Shining Light on them Shrank their Plaques more than Statins — Key Takeaways
Substack
Shining Light on them Shrank their Plaques more than Statins
Dalton (Analyze & Optimize)Mar 25, 2026
Read the original20 minutes daily of polarized red/near-infrared light (400–760 nm) applied to the ear reduced aortic plaque coverage from 57.5% to 26.4% in rabbits — outperforming statins, which only reduced it to 47.5%.
Key takeaways
Red light on ears outperformed statins at reducing arterial plaque
Red light on ears outperformed statins at reducing arterial plaque
- Rabbit atherosclerosis model: 20 min/day polarized red light (400-760nm) cut aortic plaque from 57.5% to 26.4% vs statins' 47.5%.
- Ears targeted because high vascularity means full blood volume circulates through the light field multiple times per session.
Red light reduces WBC count and platelets — two key cardiovascular risk markers
Red light reduces WBC count and platelets — two key cardiovascular risk markers
- Light-treated rabbits showed lower white blood cell counts and reduced platelet levels vs controls on high-cholesterol diet.
- Mechanism: red/NIR light activates cytochrome c oxidase, boosting mitochondrial energy that keeps immune cells from staying in activated inflammatory state.
20 min/day ear-targeted red light drives dose-dependent plaque reduction
20 min/day ear-targeted red light drives dose-dependent plaque reduction
- 5 min/day → 42.2% plaque coverage; 20 min/day → 26.4% — nearly halving plaque vs untreated high-cholesterol controls at 57.5%.
- Protocol: polarized 400-760nm light, 10 cm from ear surface, same daily window (10:00-12:00), 8 weeks. Animal study only.
This Dig holds the full set of insights, 4 flashcards, and 2 quotes — free in Homestake.
Unlock this Dig freeFree forever · No credit card required
In this piece
- Study Overview and Protocol
- Blood Marker Improvements
- Plaque Reduction Results
- Biological Mechanism
- Limitations and Service Pitch
“With 20 mins ➞ 26.4% !”
This page is a partial, transformative summary produced by Homestake. All rights to the original content remain with its creator — please support them at the source link above.